Tirzepatide
10MG
Tirzepatide is dosed at 2.5 mg–10 mg weekly via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 2.5 mg/mL. This information is for research and educational use only.
In stock | ≥99% catalog purity
Description
Product specification
Analytical Profile
Catalog data is presented for material identification and laboratory planning. Batch-specific documentation governs the supplied vial.
| RESEARCH NAME | Tirzepatide · LY3298176 |
| FORMAT | Lyophilised powder · 10 mg vial |
| MOLECULAR FORMULA | C225H348N48O68 |
| MOLECULAR MASS | 4813.45 g/mol |
| CAS REGISTRY | 2023788-19-2 |
| ANALYTICAL IDENTITY | HPLC + LC–MS |
| CATALOG CONDITION | Sealed · dry · light-protected · −20°C |
PROTOCOL LITERACY
Reconstitution Sequence
This source-derived sequence assumes a 10 mg vial and a final reference volume of 1.0 mL. The supplied product documentation remains the controlling instruction.
01
Metabolic
Prepare 1.0 mL of bacteriostatic water with sterile equipment.
02
INTRODUCE SLOWLY
Direct the liquid toward the inside wall of the vial to limit foaming.
03
DISSOLVE GENTLY
Roll or swirl with care until the material is dissolved; do not shake.
04
LABEL AND PROTECT
Record the preparation date and keep the vial protected from light.
05
COLD STORAGE
Refrigerate at 2-8°C and use within the four-week reference window.
UNRECONSTITUTED MATERIAL
-20°C
Keep frozen, dry, sealed, and protected from direct light. Minimise exposure to moisture.
After reconstitution
2-8°C
Keep refrigerated and light-protected. Do not freeze and use within 28 days.
Handling principle
DO NOT FREEZE
Allow the vial to reach room temperature before opening to reduce condensation. Do not freeze the reconstituted solution.
PROTOCOL LITERACY
Tirzepatide DOSAGE CHART
A designed reference covering concentration, weekly schedule models, reconstitution, supply planning, storage, mechanism, study observations, and administration context. It is educational material—not an individualized regimen.
VIAL CONTENT
1.0 MG
+
REFERENCE DILUENT
1.0 MG
=
STOCK CONCENTRATION
1.0 MG/ML
U-100 SCALE
1 Unit = 0.01 ml 100 mcg
01
GRADUAL 8MG MODEL
02
12 MG TRIAL CONTEXT
EDUCATIONAL REFERENCE
GRADUAL DAILY MODEL
| STUDY INTERVAL | STAGE | WEEKLY DOSE | U-100 REFERENCE | SOLUTION VOLUME |
|---|---|---|---|---|
01
WEEKS 1-4 | INITIATION | 2.5 mg | 100 UNITS | 1.0 ML |
02
WEEKS 5-8 | ESCALATION 01 | 5 MG | 100 UNITS | 1.0 ML |
03
WEEKS 9-12 | INITIATION | 7.5 MG | 100 UNITS | 1.0 ML |
04
Weeks 13–16 | UPPER REFERENCE | 10 MG | 100 UNITS | 1.0 ML |
01
REFERENCE ASSUMPTIONS
Every unit and volume value shown assumes a 10 mg vial prepared to a total reference volume of 1.0 mL.
02
MATERIAL BOUNDARY
This table does not provide preparation or administration instructions.
03
PROTOCOL CONTROL
Trial documentation and qualified clinical oversight—not this chart—must govern all dosing decisions.
Related products
-
AOD-9604
View → This product has multiple variants. The options may be chosen on the product page -
Tesamorelin
View → This product has multiple variants. The options may be chosen on the product page -
SLU-PP-332
View → This product has multiple variants. The options may be chosen on the product page -
GLP-1 | GIP | Glucagon
View → This product has multiple variants. The options may be chosen on the product page -
Cagrilintide
View → This product has multiple variants. The options may be chosen on the product page -
MOTS-C
View → This product has multiple variants. The options may be chosen on the product page
Product Enquiry
Have a question about this product? Send us your enquiry and our team will get back to you shortly.